Literature DB >> 30819364

Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review.

Eric P Stahl1, Devinder S Dhindsa2, Suegene K Lee1, Pratik B Sandesara2, Naga P Chalasani3, Laurence S Sperling4.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) are both manifestations of end-organ damage of the metabolic syndrome. Through multiple pathophysiological mechanisms, CVD and NAFLD are associated with each other. Systemic inflammation, endothelial dysfunction, hepatic insulin resistance, oxidative stress, and altered lipid metabolism are some of the mechanisms by which NAFLD increases the risk of CVD. Patients with NAFLD develop increased atherosclerosis, cardiomyopathy, and arrhythmia, which clinically result in cardiovascular morbidity and mortality. Defining the mechanisms linking these 2 diseases offers the opportunity to further develop targeted therapies. The aim of this comprehensive review is to examine the association between CVD and NAFLD and discuss the overlapping management approaches.
Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiovascular disease; metabolic syndrome; nonalcoholic fatty liver disease

Mesh:

Year:  2019        PMID: 30819364     DOI: 10.1016/j.jacc.2018.11.050

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  62 in total

1.  The correlation between hepatic fat fraction evaluated by dual-energy computed tomography and high-risk coronary plaques in patients with non-alcoholic fatty liver disease.

Authors:  Rui Zhan; Rongxing Qi; Sheng Huang; Yang Lu; Xiaoyu Wang; Jiashen Jiang; Xiwu Ruan; Anyi Song
Journal:  Jpn J Radiol       Date:  2021-04-05       Impact factor: 2.374

2.  Hepatosteatosis and Atherosclerotic Disease: Disentangling the Overlap.

Authors:  Shady Abohashem; Ron Blankstein
Journal:  Radiol Cardiothorac Imaging       Date:  2022-04-28

3.  Fragmented QRS in inferior leads is associated with non-alcholic fatty liver disease, body-mass index, and interventricular septum thickness in young men.

Authors:  Remzi Sarıkaya; Cihan Şengül; Ömer Kümet; Gürkan İmre; Tayyar Akbulut; Mustafa Oğuz
Journal:  Anatol J Cardiol       Date:  2022-02       Impact factor: 1.596

Review 4.  Epicardial and pericardial fat analysis on CT images and artificial intelligence: a literature review.

Authors:  Federico Greco; Rodrigo Salgado; Wim Van Hecke; Romualdo Del Buono; Paul M Parizel; Carlo Augusto Mallio
Journal:  Quant Imaging Med Surg       Date:  2022-03

5.  Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis.

Authors:  Ali Aminian; Abbas Al-Kurd; Rickesha Wilson; James Bena; Hana Fayazzadeh; Tavankit Singh; Vance L Albaugh; Faiz U Shariff; Noe A Rodriguez; Jian Jin; Stacy A Brethauer; Srinivasan Dasarathy; Naim Alkhouri; Philip R Schauer; Arthur J McCullough; Steven E Nissen
Journal:  JAMA       Date:  2021-11-23       Impact factor: 56.272

6.  Atherogenic index of plasma combined with waist circumference and body mass index to predict metabolic-associated fatty liver disease.

Authors:  Shao-Jie Duan; Zhi-Ying Ren; Tao Zheng; Hong-Ye Peng; Zuo-Hu Niu; Hui Xia; Jia-Liang Chen; Yuan-Chen Zhou; Rong-Rui Wang; Shu-Kun Yao
Journal:  World J Gastroenterol       Date:  2022-09-28       Impact factor: 5.374

7.  A retrospective study on the relationship between fibrosis‑4 index and all‑cause mortality in patients with acute myocardial infarction.

Authors:  Maolin Cao; Tingming Li; Zhifeng Li; Fang Gong; Zijun Chen
Journal:  Exp Ther Med       Date:  2022-08-31       Impact factor: 2.751

8.  Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease.

Authors:  Jacqueline B Henson; Tracey G Simon; Alyson Kaplan; Stephanie Osganian; Ricard Masia; Kathleen E Corey
Journal:  Aliment Pharmacol Ther       Date:  2020-02-11       Impact factor: 8.171

9.  Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.

Authors:  Tracey G Simon; Bjorn Roelstraete; Hamed Khalili; Hannes Hagström; Jonas F Ludvigsson
Journal:  Gut       Date:  2020-10-09       Impact factor: 23.059

Review 10.  NAFLD and cardiovascular diseases: a clinical review.

Authors:  Philipp Kasper; Anna Martin; Sonja Lang; Fabian Kütting; Tobias Goeser; Münevver Demir; Hans-Michael Steffen
Journal:  Clin Res Cardiol       Date:  2020-07-21       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.